Citrullinated peptides that bind to types of MHC class II and their use on diagnosis and treatment
AssigneeCurara AB
InventorsLars Klareskog, Vivianne Malmstström
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprises (a) a peptide of 8 to 20 amino acids comprising at least one citrulline residue and 13, 14 or 15 consecutive amino acids residues with a sequence present in SEQ ID NO 22 or a complex of said peptide and a human recombinant MHC class II protein, and (b) an immunologic adjuvant.
Claims10
A pharmaceutical composition comprising (a) a peptide epitope of up to 20 amino acids comprising 13, 14 or 15 consecutive amino acid residues with a sequence present in SEQ ID NO 22, and having a citrulline residue within the consecutive amino acid residues, or a complex of said peptide epitope and a human recombinant MHC class II protein, and (b) an immunologic adjuvant.
An assay for analysis of T-cells of a patient, comprising
- 1) contacting a sample comprising T cells obtained from a patient with a peptide epitope of up to 20 amino acids and comprising 13, 14 or 15 consecutive amino acid residues with a sequence present in SEQ ID NO 22, and having a citrulline residue within the consecutive amino acid residues, or a complex of said peptide epitope and a human recombinant MHC class II protein;
- and
- 2) detecting the ability of the T-cells to become activated by the peptide epitope or complex.
A method of detecting T-cell binding in a sample, the method comprising contacting a sample comprising T-cells obtained from a patient with a peptide epitope of up to 20 amino acids and comprising 13, 14 or 15 consecutive amino acid residues with a sequence present in SEQ ID NO 22, and having a citrulline residue within the consecutive amino acid residues, or with a complex of said peptide epitope and a human recombinant MHC class II protein, and detecting binding of T-cells in the sample to the peptide epitope or the complex.
A method of detecting a T-cell marker produced by T-cell binding in a sample, the method comprising contacting a sample comprising T-cells obtained from a patient with a peptide epitope of up to 20 amino acids and comprising 13, 14 or 15 consecutive amino acid residues with a sequence present in SEQ ID NO 22, and having a citrulline residue within the consecutive amino acid residues, or a complex of said peptide epitope and a human recombinant MHC class II protein, and detecting a T-cell marker produced from binding of T-cells in the sample to the peptide epitope or the complex.
A pharmaceutical composition, comprising (a) a peptide comprising SEQ ID NO:
- 22, and (b) an immunologic adjuvant.
Dependencies are inferred from the claim text.